Pluvicto's expanded indication tripled the eligible patient population. New agents are entering trials monthly. But most referring practices still lack the clinical context, financial clarity, and referral workflows to act on it. Theranostics Insider closes that gap.
Free to subscribe. Unsubscribe anytime. No spam, no vendor pitches.
You're on the list. Welcome to the briefing.
Most theranostics centers operate with only one to three referring physician relationships. The eligible patient population just tripled. Referring practices lack both the clinical clarity and the financial framework to act. That math doesn't work — and it's the problem this publication exists to solve.
Each issue is a 5-minute read covering what's changing, what it means for your practice, and exactly how to act on it.
Patient selection criteria, imaging interpretation for referral decisions, treatment sequencing, and combination therapy protocols — translated from nuclear medicine into the language of your specialty.
How the referral-to-treatment workflow actually works. Team roles, ordering panels, lab and infusion coordination, and throughput bottlenecks that delay your patients.
The revenue your practice retains when you refer for RLT — co-management billing, buy-and-bill models, payer navigation, and the financial frameworks that make referral sustainable, not punitive.
New agents approaching FDA decisions, expanded indications, reimbursement policy changes, and what's coming next — so you can plan ahead, not react.
Radioligand therapy is scaling fast. Manufacturing is expanding. The FDA is approving new indications. But the bottleneck isn't supply — it's referrals.
Most oncologists, urologists, and endocrinologists know theranostics exists. Far fewer know exactly which patients qualify, how to initiate a referral, what the care coordination looks like, or how their practice captures revenue in the process.
Theranostics Insider exists to close that gap — with clear, vendor-neutral, clinically grounded intelligence written specifically for the physicians and care teams who refer patients into these programs.
Built by professionals with 15+ years in medical imaging, PET/CT operations, and the nuclear medicine industry. Editorially independent. No manufacturer affiliations.
Clinical intelligence, financial clarity, operational playbooks, and pipeline updates — written for referring specialists and their care teams.
No spam. Unsubscribe anytime. Editorially independent, always.
You're on the list. Welcome to the briefing.